T

Tr1X

Develops cellular immunotherapies for autoimmune diseases

Principal Scientist - LNP Platform & Process Development

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeSan Diego, CA, USA

About the Job

Requirements

  • A Ph.D. in Chemical Engineering, Bioengineering, Pharmaceutical Sciences, Chemistry, or a related field with a minimum of 6 years of relevant industry experience; alternatively, an M.S. with 10 or more years of relevant industry experience or a B.S. with 12 or more years.
  • Demonstrated in-depth expertise in lipid nanoparticle formulation and process development, including hands-on experience with microfluidic or scalable mixing technologies and downstream purification strategies such as tangential flow filtration.
  • Strong experience with analytical characterization of targeted lipid nanoparticle systems and applying statistical design tools for process optimization.
  • Experience with messenger RNA therapeutics or nucleic acid delivery systems.
  • Experience conjugating targeting ligands, including antibodies, nanobodies, or peptides, to lipid nanoparticles.
  • Ability to actively serve, collaborate, and develop relationships inside and outside the organization.
  • Excellent written and oral communication skills.
  • Strong analytical and problem-solving skills, attention to detail, and ability to drive timely, fact-based decision-making.
  • Ability to function in a rapidly changing environment and handle multiple priorities.
  • Legally authorized to work for any employer in the United States.

Responsibilities

  • Lead the design, development, and optimization of lipid nanoparticle formulations for messenger RNA delivery, including targeted lipid nanoparticle systems incorporating conjugated or functionalized lipids.
  • Evaluate lipid composition, formulation parameters, and mixing conditions to optimize particle size, polydispersity, encapsulation efficiency, surface functionalization, stability, release characteristics, and biological performance.
  • Develop and optimize research-scale compatible production processes for consistently producing high-quality targeted lipid nanoparticles in-house at milligram quantities.
  • Lead development and optimization of accompanying analytical characterization methods, both in-house and at the external contract development and manufacturing organization, including dynamic light scattering, fluorescence-based assays such as Ribogreen, high-performance liquid chromatography and ultra-performance liquid chromatography methods (charged aerosol detection, ultraviolet, ion-pair reversed-phase, size-exclusion chromatography, and ion-exchange chromatography), liquid chromatography-mass spectrometry, and endotoxin testing.
  • Interpret analytical and stability data to establish meaningful correlations between physicochemical properties and biological function.
  • Collaborate with platform biology teams to support in vitro and in vivo studies, prepare development reports and technical documentation, and contribute to technology transfer activities with external contract development and manufacturing organization partners.
  • Spearhead investigational new drug-enabling documentation and contribute to defining the long-term strategy for scalable lipid nanoparticle platform development.
  • Participate in cross-functional development and manufacturing projects to ensure company objectives are met.
  • Perform other responsibilities as required based on business needs.

Desired Qualifications

  • Prior exposure to immunotherapy or in vivo cell therapy platforms.
  • Experience correlating formulation attributes with in vivo performance in mouse or non-human primate studies.
  • Experience with messenger RNA production and analytical quality control.

About the Company

Tr1X

Develops cellular immunotherapies for autoimmune diseases

Tr1X focuses on cellular immunotherapies for autoimmune and inflammatory diseases. Using a proprietary platform, it creates first-in-class cell therapy products that aim to rebalance the immune system and restore homeostasis, achieving long-term tolerance. The company develops and commercializes these therapies, generating revenue through partnerships, licensing, and direct sales, with a business base in La Jolla, CA. How it works: the core product is a cell therapy designed to modulate immune responses so the body reaches stable immune balance rather than ongoing suppression. This differs from many competitors by emphasizing durable immune tolerance via a proprietary platform and by pursuing partnerships and licensing to bring therapies to healthcare providers and patients. The goal is to deliver durable immune tolerance for autoimmune and inflammatory diseases through first-in-class cell therapies.

Company size
11-50
Company stage
Early VC
Total funding
$125M
Headquarters
San Diego, CA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Tr1X

See more jobs